Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives.
暂无分享,去创建一个
Daniel J. Freeman | Hongyu Liao | Nancy Zhang | J. McCarter | Nancy Zhang | D. Whittington | R. Subramanian | Yunxin Y Bo | N. Nishimura | S. Caenepeel | H. Liao | Longbin Liu | Aaron C. Siegmund | S. Booker | Kevin C Yang | Douglas A Whittington | Leeanne P Zalameda | John McCarter | Raju Subramanian | Paul E Hughes | Sean Caenepeel | M. Bryan | E. Mullady | Marian C Bryan | Mark H Norman | Longbin Liu | Leeanne Zalameda | Tisha San Miguel | Erin L Mullady | Ling Wang | Kevin Yang | Nuria Tamayo | Nobuko Nishimura | Aaron Siegmund | Kristin L Andrews | Yunxin Bo | Shon K Booker | Daniel Freeman | P. Hughes | Nuria Tamayo | Ling Wang | K. Andrews | M. H. Norman | Tisha San Miguel
[1] Haoran Sun,et al. Room-temperature nucleophilic aromatic fluorination: experimental and theoretical studies. , 2006, Angewandte Chemie.
[2] Ji Luo,et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.
[3] Kaushik Raha,et al. Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. , 2010, ACS medicinal chemistry letters.
[4] Pixu Liu,et al. Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.
[5] Paul Workman,et al. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. , 2008, Current opinion in pharmacology.
[6] G. Bemis,et al. Kinase inhibitors and the case for CH…O hydrogen bonds in protein–ligand binding , 2002, Proteins.
[7] Robbie Loewith,et al. A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.
[8] A. Albert. Hydration of cn bonds in heteroaromatic substances , 1967 .
[9] Nathan T. Ihle,et al. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy , 2009, Molecular Cancer Therapeutics.
[10] I. H. Pitman,et al. Linear free energy relations governing the covalent addition of nucleophilic reagents to a nitrogen-containing heteroaromatic molecule , 1974 .
[11] Akira Suzuki,et al. Recent advances in the cross-coupling reactions of organoboron derivatives with organic electrophiles, 1995–1998 , 1999 .
[12] Daniel J. Freeman,et al. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors. , 2011, Journal of medicinal chemistry.
[13] Lewis C Cantley,et al. The phosphoinositide 3-kinase pathway. , 2002, Science.